title: Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P).
abstract: To establish diagnostic accuracy (acc) and optimal cut-off levels of CSF tau phosphorylated at threonine 181 (P-tau(181P)) for discriminating Alzheimer's disease (AD) from non-AD dementias in autopsy-confirmed dementia patients, CSF levels of beta-amyloid peptide (Abeta(1-42)), total tau protein (T-tau) and P-tau(181P) from patients with definite AD (n=95) and non-AD dementias (n=50) were determined with single-parameter ELISA kits. Optimal P-tau(181P) cut-off levels for differentiating AD from pooled non-AD dementias, dementia with Lewy bodies (DLB) and frontotemporal dementia (FTD) were 50.4pg/mL (acc=0.73), 52.8pg/mL (acc=0.73) and 35.3pg/mL (acc=0.90), respectively. The optimal CSF P-tau(181P) cut-off level for discriminating AD from non-AD dementias was 50.4pg/mL. Optimal CSF P-tau(181P) cut-off levels differed between non-AD diagnostic dementia categories.
authors.affiliation: Department of Neurology and Memory Clinic, Middelheim General Hospital (ZNA), Antwerp, Belgium; Department of Neurology, University Medical Center Groningen, Groningen, The Netherlands.
authors.forename: Karen
authors.initials: K
authors.lastname: Koopman
authors.forename: Nathalie
authors.initials: N
authors.lastname: Le Bastard
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Martin
authors.forename: Guy
authors.initials: G
authors.lastname: Nagels
authors.forename: Peter P
authors.initials: PP
authors.lastname: De Deyn
authors.forename: Sebastiaan
authors.initials: S
authors.lastname: Engelborghs
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000175:diagnosis*; D000595:Amino Acid Sequence / Q000502:physiology; D016229:Amyloid beta-Peptides / Q000032:analysis / Q000134:cerebrospinal fluid; D001344:Autopsy; D015415:Biomarkers / Q000032:analysis / Q000134:cerebrospinal fluid; D001921:Brain / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D020134:Catalytic Domain; D003704:Dementia / Q000175:diagnosis*; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D008297:Male; D016874:Neurofibrillary Tangles / Q000378:metabolism / Q000473:pathology; D010446:Peptide Fragments / Q000032:analysis / Q000134:cerebrospinal fluid; D010766:Phosphorylation; D058225:Plaque, Amyloid / Q000378:metabolism; D011237:Predictive Value of Tests; D012680:Sensitivity and Specificity; D013912:Threonine / Q000378:metabolism; D016875:tau Proteins / Q000032:analysis / Q000134:cerebrospinal fluid* / Q000737:chemistry
chemical_list: D016229:Amyloid beta-Peptides; D015415:Biomarkers; C054369:MAPT protein, human; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); D016875:tau Proteins; D013912:Threonine